Morningstar

Eisai Co Ltd ESALF

Morningstar Rating

Lecanemab Fails to Get EU Marketing Approval; Eisai to Seek Reexamination

Global News Select Jul 26, 2024 12:15pm
Biogen's stock stumbles as Alzheimer's drug is rejected by European regulators

MarketWatch Jul 26, 2024 12:06pm
Eli Lilly's Alzheimer's drug wins FDA approval

MarketWatch Jul 2, 2024 6:59pm
Eli Lilly's Alzheimer's drug gets backing from FDA advisers

MarketWatch Jun 10, 2024 8:37pm
Eli Lilly's Alzheimer's drug to face safety, dosing scrutiny from FDA advisers

MarketWatch Jun 7, 2024 12:45pm
Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves

MarketWatch Apr 24, 2024 12:08pm
Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

MarketWatch Dec 8, 2023 12:56pm
Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study

Global News Select Dec 8, 2023 12:21pm
Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

MarketWatch Oct 25, 2023 9:28pm
Merck, Eisai: Keytruda/Lenvima Combo Fails in Two Non-Small Cell Lung Cancer Studies

Global News Select Sep 22, 2023 11:31am
Merck and Eisai say two lung-cancer trials failed to meet their main goals

MarketWatch Sep 22, 2023 11:31am
Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals

MarketWatch Aug 25, 2023 10:54am

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.